Novo provides update on the denecimig Biologics License Application (BLA) in the US

{
  "signal_id": "a8707d89-98b8-eeac-49cd-165df786a683",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-10-02T20:53:00+00:00",
  "company": {
    "name": "Novo Nordisk",
    "domain": "novonordisk.com"
  },
  "data": {
    "url": "https://www.globenewswire.com/news-release/2026/10/02/3374048/0/en/novo-provides-update-on-the-denecimig-biologics-license-application-bla-in-the-us.html",
    "title": "Novo provides update on the denecimig Biologics License Application (BLA) in the US",
    "excerpt": "Bagsværd, Denmark, 02 October 2026 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has informed Novo that the BLA review of denecimig for the treatment of haemophilia A, with or without inhibitors in adults and children, is still ongoing. The FDA has not communicated a new timeline for expected regulatory action on the BLA. Novo submitted a BLA for denecimig for the treatment of haemophilia A in adult and paediatric patients to the US FDA for review in September 2025, with an anticipated regulatory decision in the third quarter of 2026. Following this submission, the FDA performed a pre-license inspection of the manufacturing site and provided feedback. Today, the FDA has informed Novo that the ongoing facility remediation activities are the cause for extension of the Agency's review. “Haemophilia A patients should expect more from their standard of care,” said Mike Doustdar, president and CEO of Novo. “As Novo prepares to bring denecimig to market, our ambition is to help make better care something they can count on. Novo is already in the process of addressing the FDA's requests as efficiently as possible and continuing to work closely with the Agency toward bringing denecimig to patients in the US.” The Agency has not identified deficiencies related to the clinical efficacy or safety data of denecimig demonstrated in the FRONTIER clinical trial...",
    "product": "denecimig",
    "summary": "Novo Nordisk is developing denecimig, a treatment for haemophilia A, and aims to launch it in the US in the first half of 2027, pending regulatory approval.",
    "location": "United States",
    "planning": true,
    "image_url": "https://ml-eu.globenewswire.com/Resource/Download/f87e6f85-3e50-4571-b9e5-8f683431f855",
    "confidence": 0.9,
    "product_data": {
      "name": "denecimig",
      "full_text": "denecimig for the treatment of haemophilia A",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical",
      "general_technology"
    ],
    "published_at": "2026-10-02T20:53:00Z",
    "location_data": [
      {
        "region": "Northern America",
        "country": "United States",
        "continent": "Americas",
        "fuzzy_match": false
      }
    ],
    "article_sentence": "Pending regulatory decision, Novo aims to launch denecimig in the US in the first half of 2027."
  }
}

curl https://signals.autobound.ai/v1/signals/a8707d89-98b8-eeac-49cd-165df786a683 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"novonordisk.com","limit":20}'